- Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trials
- For the primary endpoint, 25.4% of children treated once daily with roflumilast cream 0.05% achieved Investigator Global Assessment (IGA) Success compared to 10.7% of children treated with vehicle (P
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
On 6ix: 6ix.com/news/arcutis-announces-positive-results-from-integument-ped-pivotal-phase-3-trial-of
Arcutis Biotherapeutics, Inc. on 6ix
Story so far
- Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
- Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
- Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
Earlier from Arcutis Biotherapeutics
- Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
- Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
- Arcutis to Present at Upcoming Investor Conference
- Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
- Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
Later from Arcutis Biotherapeutics
- New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
- Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
- FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
- Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
- Arcutis Announces Pricing of $100 Million Public Offering
Follow Arcutis Biotherapeutics into a list and get an email when it puts out news.
Follow Arcutis Biotherapeutics